Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O14732
UPID:
IMPA2_HUMAN
Alternative names:
Inositol-1(or 4)-monophosphatase 2; Myo-inositol monophosphatase A2
Alternative UPACC:
O14732; B0YJ29; Q9UJT3
Background:
Inositol monophosphatase 2, also known as Myo-inositol monophosphatase A2, plays a crucial role in the phosphatidylinositol signaling pathway by metabolizing myo-inositol monophosphates. This enzyme's ability to act on a variety of substrates, including scylloinositol 1,4-diphosphate and glucose-1-phosphate, underscores its versatility in cellular processes.
Therapeutic significance:
Understanding the role of Inositol monophosphatase 2 could open doors to potential therapeutic strategies. Its involvement in the brain's response to lithium Li(+) suggests a significant impact on mental health treatment, particularly in mood disorders.